Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 1.9% – Should You Buy?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX)’s stock price was up 1.9% on Thursday . The company traded as high as $3.27 and last traded at $3.24. Approximately 15,739 shares changed hands during trading, an increase of 86% from the average daily volume of 8,450 shares. The stock had previously closed at $3.18.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on EPRX shares. Rodman & Renshaw started coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th.

Eupraxia Pharmaceuticals Price Performance

The company’s 50-day simple moving average is $3.12 and its 200-day simple moving average is $2.88. The company has a market cap of $115.41 million and a price-to-earnings ratio of -4.50.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. Raymond James Financial Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,613 shares of the company’s stock, valued at approximately $37,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.